Products
Preparation registered in Ukraine
Mitchenko O., Romanov V., Beliaeva T., Chulaievska I.
Experience in using the drug Livostor in patients with coronary heart disease and type 2 diabetes
In this article the favorable effect of lipid lowering therapy on complications and mortality caused by coronary disease is explored. The data of its effectiveness during the primary and secondary prevention is put. In a study involving 30 patients high hypolipidemic efficacy of Livostor (“Kyiv Vitamin Factory”) at a dose of 10 mg OD for 12 weeks in patients with ischemic heart disease was demonstrated. With Livostor therapy target levels of elevated total cholesterol and LDL cholesterol were achieved. Moderate hypolipidemic efficacy in patients with ischemic heart disease and type 2 diabetes was also demonstrated.
Key words: coronary heart disease, diabetes, lipid lowering therapy, atorvastatin, Livostor.